Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Data from more than 20 company-sponsored ... landscapes for patients with bladder and prostate cancers," said Karin Tollefson, Chief Oncology Medical Officer, Pfizer. "Our strong presence at ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best big name stocks to invest in now. Big name stocks refer to well-known companies ...

Data from more than 20 company-sponsored, investigator-sponsored ... the treatment landscapes for patients with bladder and prostate cancers," said Karin Tollefson, Chief Oncology Medical Officer, ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks. During a time of great excitement about AI-driven capital gains ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer’s radar. Jim Cramer, host of Mad Money, shared his thoughts ...